| |
Shanghai Genomics,Inc, a drug discovery/development company was founded in August 2001, by returnees Dr. Ying Luo and Dr. Jun Wu, with funding of 43 million RMB from Shanghai Venture Capital Company and Shanghai Zhangjiang Hi-Tech Park Corp. In 2005, the company merged with GNI. The company currently employs more than 100 people with about 80% in R&D, including 17 Ph.D. scientists. Shanghai Genomics occupies 40,000-square-foot buildings located in the dynamic metropolitan Shanghai, which is one of the most modern laboratory facilities in China. The company went public on the Tokyo Stock Exchange on August 31, 2007.
Our mission is to develop novel therapeutic products for diseases prevalent in Asian, especially in the areas of lung
fibrosis, liver fibrosis, cancer, and new biomaterials for bone healing. Leveraging our highly efficient drug registration
team and extensive nationwide clinical research network, we provide drug registration service and clinical CRO. Shanghai
Genomics has also built an integrated drug discovery and development platform, including signaling pathway mapping, gene
expression profile studies, protein expression and purification, knock-down/knock-out, in vivo animal modeling, antibody
generation and purification, and bioinformatics. These programs have resulted in contract/collaborative research services
with pharmaceutical companies worldwide. Our research reagent products have been sold to research institutes, hospitals and
companies globally.
Shanghai Genomics has received extensive coverage by worldwide media such as the Wall Street Journal, Asian Wall Street Journal and many other well-known media in China for our well-trained technical staff and outstanding research capabilities. The founders of Shanghai Genomics were frequently invited to international conferences to introduce the fast growing Chinese bio-pharmaceutical companies. We believe that our sophisticated multiple platforms, advanced technology and instruments, highly efficient research group and modern management concept, will surely bring Shanghai Genomics a promising future!
|
|
 |
